These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34645381)

  • 1. Pharmacotherapy for SARS-CoV-2 and Seizures for Drug Repurposing Presumed on Mechanistic Targets.
    Goel D; Srivastava A; Aledo-Serrano Á; Krishnan A; Vohora D
    Curr Mol Pharmacol; 2022; 15(6):832-845. PubMed ID: 34645381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing Multiple-Molecule Drugs for COVID-19-Associated Acute Respiratory Distress Syndrome and Non-Viral Acute Respiratory Distress Syndrome via a Systems Biology Approach and a DNN-DTI Model Based on Five Drug Design Specifications.
    Ting CT; Chen BS
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
    Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK
    Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing Drugs for COVID-19: An Approach for Treatment in the Pandemic.
    Khadka S; Yuchi A; Shrestha DB; Budhathoki P; Al-Subari SMM; Ziad Alhouzani TM; Anwar Butt I
    Altern Ther Health Med; 2020 Aug; 26(S2):100-107. PubMed ID: 32827400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurological manifestations of COVID-19: available evidences and a new paradigm.
    Khatoon F; Prasad K; Kumar V
    J Neurovirol; 2020 Oct; 26(5):619-630. PubMed ID: 32839951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can dexamethasone prevent the seizures induced by SARS-CoV-2 infection?
    Vizuete AFK; Gonçalves CA
    Mult Scler Relat Disord; 2021 Jan; 47():102606. PubMed ID: 33137605
    [No Abstract]   [Full Text] [Related]  

  • 9. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
    Mishra J; Prasun C; Sahoo PK; Nair MS
    Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?
    Rakedzon S; Neuberger A; Domb AJ; Petersiel N; Schwartz E
    J Travel Med; 2021 Feb; 28(2):. PubMed ID: 33480414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach.
    Parvez MSA; Karim MA; Hasan M; Jaman J; Karim Z; Tahsin T; Hasan MN; Hosen MJ
    Int J Biol Macromol; 2020 Nov; 163():1787-1797. PubMed ID: 32950529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 infection of the nervous system: A review of the literature on neurological involvement in novel coronavirus disease-(COVID-19).
    Payus AO; Liew Sat Lin C; Mohd Noh M; Jeffree MS; Ali RA
    Bosn J Basic Med Sci; 2020 Aug; 20(3):283-292. PubMed ID: 32530389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing.
    Das AB
    BMC Med Genomics; 2021 Sep; 14(1):226. PubMed ID: 34535131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
    Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
    Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response.
    Başaran S; Şimşek-Yavuz S; Meşe S; Çağatay A; Medetalibeyoğlu A; Öncül O; Özsüt H; Ağaçfidan A; Gül A; Eraksoy H
    Int J Infect Dis; 2021 Apr; 105():756-762. PubMed ID: 33737128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of SARS-CoV-2 infection on seizure, anxiety, and depression in 107 patients with epilepsy.
    Zhou S; Zhang D; Chang J; Xia Z; Li J; Ni M; Li H
    Epilepsy Behav; 2023 Aug; 145():109290. PubMed ID: 37406559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors.
    Fiorucci D; Milletti E; Orofino F; Brizzi A; Mugnaini C; Corelli F
    J Biomol Struct Dyn; 2021 Oct; 39(16):6242-6248. PubMed ID: 32705942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability.
    Debnath SK; Debnath M; Srivastava R; Omri A
    Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1187-1204. PubMed ID: 35615888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. INCIDENCE OF ACUTE SYMPTOMATIC SEIZURES 
IN PATIENTS WITH COVID-19: A SINGLE-CENTER STUDY.
    Šušak Sporiš I; Sporiš D; Čolak Romić Z; Bago Rožanković P; Bašić S
    Acta Clin Croat; 2021 Dec; 60(Suppl 3):50-56. PubMed ID: 36404999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.